Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 2

Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis

NCT05636228 · View on ClinicalTrials.gov ↗

Study Summary

Phase 2, randomized study to assess topically administered eyedrops of INV-102 compared to vehicle during 1-week dosing in participants with Acute Infectious Keratoconjunctivitis (AIK). Participants will return for a follow up visit 1 week after end of treatment.

Interventions

  • DRUG Vehicle
  • DRUG INV-102

Study Locations (12)

Florida

  • Shettle Eye Research — Largo
  • D & H National Research Centers, INC — Miami
  • My Community Research Center, Inc. — Miami
  • Quantum Clinical Trials — Miami Beach

California

  • Global Research Management — Glendale
  • Foothill Eye Institute — Pasadena

Other

  • King Chulalongkorn Memorial Hospital — Bangkok
  • Mahidol university — Bangkok

Kansas

  • Kannarr Eye Center — Pittsburg

North Carolina

  • Oculos Clinical Research — Garner

Ohio

  • Athens Eye Care — Athens

Texas

  • Revolution Research/ Lake Travis Eye and Laser Center — Lakeway

Trial Details

FieldValue
Enrollment Target 93 participants
Start Date 2023-06-09
Est. Completion 2024-08-22
Phase Phase 2

Sponsor

Invirsa

2 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05636228

The ClinicalTrials.gov registry entry for NCT05636228 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Invirsa, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Acute Infectious Keratoconjunctivitis appearing as the primary indexed condition, and to 2 interventions — of which Vehicle is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05636228 reports 12 study locations spanning 7 distinct geographic areas — top geographies include Florida, California, Other. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05636228 about?

NCT05636228 is a clinical study titled "Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis". Phase 2, randomized study to assess topically administered eyedrops of INV-102 compared to vehicle during 1-week dosing in participants with Acute Infectious Keratoconjunctivitis (AIK). Participants will return for a follow up visit 1 week after end of treatment.

What is the current status of trial NCT05636228?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2023-06-09. Estimated completion is 2024-08-22.

What conditions does trial NCT05636228 study?

This clinical trial studies the following conditions: Acute Infectious Keratoconjunctivitis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05636228?

The interventions under investigation include: Vehicle (DRUG), INV-102 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05636228?

This trial is sponsored by Invirsa, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05636228 being conducted?

This trial has 12 study locations across California, Florida, Kansas, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial